| 证券代码 | ZSAN.O |
| 证券名称 | Zosano Pharma Corp |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | 主板 |
| 发行方式 | 公开发售 |
| 首发上市日 | 2015-01-27 |
| 首发价格(元) | 11 USD |
| 首发数量(股) | 4500000 |
| 首发募资额(元) | 49,500,000.00 USD |
| 首发主承销商 | Roth Capital Partners, Inc,Ladenburg Thalmann and Co. Inc |
| 货币单位 | USD |
| 公司名称 | Zosano Pharma Corporation |
| 注册地址 | 美国特拉华州 |
| 办公地址 | 34790 Ardentech Court, Fremont, California, USA |
| 成立日期 | 2012-01 |
| 董事会主席 | - |
| 公司属地 | United States 美国 |
| 公司网址 | www.zosanopharma.com |
| 电话 | +1 (510) 745-1200 |
| 传真 | - |
| 公司简介 | Zosano Pharma Corporation is a clinical-stage biopharmaceutical company focused on providing systemic administration of therapeutics to patients using their proprietary Adhesive Dermally-Applied Microarray, or ADAM technology. Their lead clinical asset, M207, has completed the pivotal ZOTRIP trial. Zosano is focused on developing products where rapid administration of established molecules with known safety and efficacy profiles provides an increased benefit to patients, for markets where patients remain underserved by existing therapies. |